Analysts Anticipate ICON Public Limited (NASDAQ:ICLR) Will Announce Quarterly Sales of $846.05 Million

Equities research analysts expect that ICON Public Limited (NASDAQ:ICLR) will announce sales of $846.05 million for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for ICON Public’s earnings, with the lowest sales estimate coming in at $804.99 million and the highest estimate coming in at $867.40 million. ICON Public posted sales of $620.23 million during the same quarter last year, which suggests a positive year-over-year growth rate of 36.4%. The company is expected to announce its next quarterly earnings report on Wednesday, July 28th.

According to Zacks, analysts expect that ICON Public will report full year sales of $3.43 billion for the current financial year, with estimates ranging from $3.24 billion to $3.47 billion. For the next year, analysts anticipate that the business will post sales of $3.67 billion, with estimates ranging from $3.43 billion to $3.78 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that cover ICON Public.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Tuesday, April 27th. The medical research company reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $1.97 by $0.09. ICON Public had a net margin of 11.49% and a return on equity of 20.70%. The company had revenue of $858.20 million for the quarter, compared to analysts’ expectations of $780.49 million.

A number of analysts have issued reports on ICLR shares. Credit Suisse Group boosted their price target on shares of ICON Public from $240.00 to $245.00 and gave the stock an “outperform” rating in a research note on Thursday, April 29th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of ICON Public from $179.00 to $208.00 and gave the stock a “hold” rating in a research note on Thursday, February 25th. Jefferies Financial Group boosted their price target on shares of ICON Public from $256.00 to $267.00 and gave the stock a “buy” rating in a research note on Thursday, April 29th. Wells Fargo & Company upgraded shares of ICON Public from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $200.00 to $235.00 in a research note on Thursday, April 1st. Finally, Zacks Investment Research lowered shares of ICON Public from a “hold” rating to a “sell” rating in a research note on Thursday, February 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. ICON Public currently has an average rating of “Buy” and a consensus target price of $232.60.

NASDAQ:ICLR traded down $2.24 on Friday, reaching $217.80. 602,649 shares of the company’s stock were exchanged, compared to its average volume of 567,320. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. The stock has a market cap of $11.68 billion, a price-to-earnings ratio of 34.24, a price-to-earnings-growth ratio of 2.19 and a beta of 0.85. The business has a fifty day simple moving average of $216.29. ICON Public has a 52-week low of $155.28 and a 52-week high of $234.22.

A number of institutional investors and hedge funds have recently made changes to their positions in ICLR. Amundi Pioneer Asset Management Inc. boosted its holdings in ICON Public by 2.1% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 24,400 shares of the medical research company’s stock valued at $3,332,000 after purchasing an additional 500 shares in the last quarter. Todd Asset Management LLC boosted its holdings in ICON Public by 18.6% in the fourth quarter. Todd Asset Management LLC now owns 103,487 shares of the medical research company’s stock valued at $20,177,000 after purchasing an additional 16,225 shares in the last quarter. FDx Advisors Inc. boosted its holdings in ICON Public by 16.2% in the fourth quarter. FDx Advisors Inc. now owns 9,792 shares of the medical research company’s stock valued at $1,909,000 after purchasing an additional 1,365 shares in the last quarter. Fayez Sarofim & Co boosted its holdings in ICON Public by 54.4% in the fourth quarter. Fayez Sarofim & Co now owns 3,180 shares of the medical research company’s stock valued at $620,000 after purchasing an additional 1,120 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its holdings in ICON Public by 23.7% in the fourth quarter. Handelsbanken Fonder AB now owns 18,430 shares of the medical research company’s stock valued at $3,593,000 after purchasing an additional 3,530 shares in the last quarter. 92.84% of the stock is owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: Understanding dividend yield and dividend payout ratio

Get a free copy of the Zacks research report on ICON Public (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ICON Public (NASDAQ:ICLR)

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.